Navigation Links
CytRx Reports Promising Data from Its Open-Label Extension Clinical,Trial of Arimoclomol in ALS

ear with a four-fold arimoclomol dose increase, subject to FDA clearance.

"We are encouraged by the favorable results of this open-label trial, which make us even more eager to proceed at an even higher dose level in further clinical testing," stated CytRx's President and CEO Steven A. Kriegsman. "The comparison of these clinical results with historical data suggests a trend toward clinical improvement. Our Phase IIb efficacy study will be placebo-controlled and is planned to include a larger number of volunteers, treated for a longer period of time with a four-fold higher dose than that used in the open-label clinical trial."

The open-label extension clinical trial was initiated in February 2006 as ALS volunteers completing CytRx's placebo-controlled, double-blind, dose-ranging Phase IIa clinical trial were provided the opportunity to receive arimoclomol treatment for up to an additional six months. A total of 69 patients were treated in the open-label arimoclomol trial for six months, while the historical control followed 99 subjects for 12 months.

In the open-label trial, arimoclomol treatment was demonstrated to be safe as indicated by the lack of clinically-significant changes in vital signs and laboratory values, compared to baseline values. Arimoclomol was also well-tolerated with a total drop-out rate of 11.6%, or an average of 1.3% per month, during the six-month trial. This compares favorably with the historical control drop-out rate of 33.3%, or an average of 2.75% per month, for the 12-month trial.

CytRx's planned Phase IIb clinical trial is currently expected to include approximately 390 ALS patients enrolled at 30 to 35 U.S. and Canadian clinical sites treated for nine months. The trial is expected to be completed approximately 18 months after enrollment begins.

About CytRx Corporation

CytRx Corporation is a biopharmaceutical research and development company engaged in the development of high-value human therap
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. CytRx Announces Clinical Results from Its Rising Multiple Dose Trial with Arimoclomol for ALS
2. CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal
3. CytRx Announces Positive Results of Arimoclomol in Preclinical Stroke Recovery Studies
4. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
5. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
6. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
7. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
8. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
9. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
10. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
11. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
Post Your Comments:
(Date:11/21/2014)... , Nov. 21, 2014 ... the European Medicines Agency (EMA) has granted ... company,s lead product candidate, for the treatment ... a rare, severely disabling genetic disease characterized ... swelling (flare-ups) and new abnormal bone formation. ...
(Date:11/21/2014)... 20, 2014  RedRick Technologies, a provider of ... room environment guidance, has helped the new Penn ... room, which may also serve as a model ... "In line with the tenets ... Radiology,s Imaging 3.0 ™ initiative, the new ...
(Date:11/21/2014)... CORAL GABLES, Fla. , Nov. 20, 2014 /PRNewswire/ ... working to become the first U.S. commercial producer of ... signed a contract with INVAP to design ... Alachua, Fla. Mo-99 is the parent isotope ... nuclear medicine procedures worldwide. In 2012, Congress passed legislation ...
Breaking Medicine Technology:Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 2Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 3RedRick Technologies Helps Penn Radiology Implement New Radiology Reading Room Concepts 2RedRick Technologies Helps Penn Radiology Implement New Radiology Reading Room Concepts 3Coqui RadioPharmaceuticals Inks Deal With INVAP 2
... Trust, Inc. (NYSE: BMR ) announced ... with Omeros Corporation (NASDAQ: OMER ) ... Seattle, Washington.  A clinical-stage biopharmaceutical company committed to ... coagulopathies and disorders of the central nervous system, Omeros ...
... Feb. 1, 2012 Novartis announced today that following ... (FDA) has approved an update to the Gleevec ® ... of treatment after surgery for adult patients with KIT ... of recurrence inclusion criteria of the pivotal trial. This ...
Cached Medicine Technology:BioMed Realty and Omeros Sign New 64,500 Square Foot Lease in Seattle 2BioMed Realty and Omeros Sign New 64,500 Square Foot Lease in Seattle 3BioMed Realty and Omeros Sign New 64,500 Square Foot Lease in Seattle 4FDA approves Novartis drug Gleevec® label recommending extending treatment to three years for certain GIST patients after surgery 2FDA approves Novartis drug Gleevec® label recommending extending treatment to three years for certain GIST patients after surgery 3FDA approves Novartis drug Gleevec® label recommending extending treatment to three years for certain GIST patients after surgery 4FDA approves Novartis drug Gleevec® label recommending extending treatment to three years for certain GIST patients after surgery 5FDA approves Novartis drug Gleevec® label recommending extending treatment to three years for certain GIST patients after surgery 6FDA approves Novartis drug Gleevec® label recommending extending treatment to three years for certain GIST patients after surgery 7FDA approves Novartis drug Gleevec® label recommending extending treatment to three years for certain GIST patients after surgery 8
(Date:11/23/2014)... November 23, 2014 The FDA is ... Common, **FDAnews On-Demand Webinar**, Dec. 11, 2014 ? Any ... The FDA’s focus on promotional activities is no longer ... Now they're looking at websites, Twitter, journal articles, TV ... for Thursday, Dec. 11, for On-Demand access to Timothy ...
(Date:11/23/2014)... 23, 2014 BambooFlooringChina.com , the world’s ... click strand woven bamboo flooring collection. Now, the business ... the company’s CEO, the promotion is valid until Dec. 20, ... with a smooth and dust-free surface, which makes it very ... the industry, the company wants to make its website the ...
(Date:11/22/2014)... A new AlignLife Chiropractic & Natural ... downtown Greenville area. Dr. Chelsea Sineath, owner and chiropractor ... open her own clinic after working in another AlignLife ... , AlignLife believes that the body can heal ... on chiropractic care and rehabilitation to allow the spine ...
(Date:11/22/2014)... November 23, 2014 Recently, UWDress.com, a successful ... formal wedding guest attire in order to prepare for ... prices, up to 70% off. , UWDress.com is a ... are very beautiful, especially the new items -- formal wedding ... in the current market, including superstar and princess. As one ...
(Date:11/22/2014)... BambooFlooringChina.com is a famous brand in the ... new collection of bamboo mats ; the new models ... , According to the sales manager of BambooFlooringChina.com, ... a highly renewable resource. Their bamboo mats are 100% made ... comes from natural bamboo with caramel bamboo strips. ...
Breaking Medicine News(10 mins):Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 2Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 3Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 4Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 5Health News:Click Strand Woven Bamboo Flooring From Famous Bamboo Flooring Company BambooFlooringChina.com 2Health News:AlignLife of Downtown Greenville is Now Open and Accepting New Patients 2Health News:Formal Wedding Guest Attire Added to UWDress.com 2Health News:Trendy Bamboo Mats Online Now By BambooFlooringChina.com 2
... ... company, now offers their clients a choice between a Flat Fee Plan and a Monthly ... Miami, FL ... cash strapped plaintiffs don’t have to wait for their lawsuits to recover, they can get ...
... NASHVILLE, Tenn., Dec. 10 Pathological gambling can be ... inhibitions, according to researchers at the annual meeting of ... outcomes in gamblers treated with medications often used for ... his team at the University of Minnesota used tasks ...
... The 2009 American College of Neuropsychopharmacology Annual Meeting ... schizophrenia and treatment for gambling addiction. Study highlights ... Techniques to Assess PTSD. Working with Iraq and ... may be useful to evaluate PTSD and develop ...
... ... a leading neurologist, Dr. Alexander Mauskop, renowned headache expert and founder of the New ... ... 9, 2009 -- A powerful headache medicine developed by a leading neurologist for his ...
... , WARRINGTON, Pa., Dec. 9 Last year Special Equestrians was ... part of $25,000 in PR service grants. "We,ve always taken corporate ... a warm and fuzzy feeling to do what little we can ... co-founder, Christopher L. Simmons. "We learned many years ago that it ...
... Award Will Create New Construction and Permanent Jobs in the South ... Additional 12,000 Residents , NEW YORK, Dec. 9 ... Reinvestment Act (Recovery Act) grant to support a new addition to ... announced by President Barack Obama as part of his plan to ...
Cached Medicine News:Health News:Injury Funds Now To the Rescue with New Lawsuit Funding Service 2Health News:Pathological Gambling May Be Successfully Treated With Medications for Substance Addiction 2Health News:Late-breaking brain and behavior research presented at ACNP annual meeting this week 2Health News:Breakthrough Approach to Age-old Ailment, Renowned Doctor Introduces Powerful Headache Medicine 2Health News:Breakthrough Approach to Age-old Ailment, Renowned Doctor Introduces Powerful Headache Medicine 3Health News:Nonprofit Partners With PR Company and Gains International Attention 2Health News:$12 Million American Recovery and Reinvestment Act Grant Awarded to Urban Health Plan, Inc. (UHP) 2Health News:$12 Million American Recovery and Reinvestment Act Grant Awarded to Urban Health Plan, Inc. (UHP) 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: